TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4008123

Group type: EXPERIMENTAL
Intervention: Peer-managed self-control program (self-monitoring, peer-assisted self-control training, alcohol education)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Minimal program intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Full program intervention
Number of subjects: 30
Study: 28001016

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg) before breakfast for 90 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 27514368

Group type: EXPERIMENTAL
Intervention: 7 Day Physical Activity Recall Questionnaire (7D‐PAR)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Accelerometer
Number of subjects: 215

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 215
Study: 24714415

Group type: EXPERIMENTAL
Intervention: AST‐120 plus once‐monthly administration of continuous EPO receptor activator (CERA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: CERA alone
Number of subjects: 51
Study: 22390992

Group type: EXPERIMENTAL
Intervention: Pajunk echogenic needle
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Braun echogenic needle
Number of subjects: 144

Group type: COMPARATOR
Intervention: Braun standard needle
Number of subjects: 144
Study: 20369705

Group type: EXPERIMENTAL
Intervention: Qianlie Jiedu Capsule + Rufloxacin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo + Rufloxacin
Number of subjects: 80
Study: 19080291

Group type: EXPERIMENTAL
Intervention: Continuous aspiration of subglottic secretions (CASS)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No aspiration of subglottic secretions (NASS)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: CASS
Number of subjects: 101

Group type: COMPARATOR
Intervention: NASS
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Failed early aspiration (volume of first daily aspirated secretions ≤ 20 ml)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Patients with VAP
Number of subjects: 101
Study: 15687530

Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study: 11826413

Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 91

Group type: COMPARATOR
Intervention: Drug therapy (propranolol + isosorbide‐5‐mononitrate)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 91
Study: 10463324

Group type: EXPERIMENTAL
Intervention: Zolmitriptan (5 mg orally)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ketanserin (5-HT receptor antagonist)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7547098

Group type: EXPERIMENTAL
Intervention: Tenidap sodium 40 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tenidap sodium 120 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2170088

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Urine glucose testing
Number of subjects: 54
Study: 7022736

Group type: EXPERIMENTAL
Intervention: Atropine sulphate (4 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atropine methonitrate (2 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fenoterol (400 μg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of atropine methonitrate with fenoterol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of atropine sulphate with fenoterol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29781725

Group type: EXPERIMENTAL
Intervention: Expanded cognitive stimulation therapy (CST) model combined with tai chi, 14 sessions, twice a week
Number of subjects: 101

Group type: COMPARATOR
Intervention: Waitlist control group received treatment as usual initially and expanded CST model later
Number of subjects: 101
Study: 28629222

Group type: EXPERIMENTAL
Intervention: Parental Self-Efficacy (PSE)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Parental Self-Efficacy (PSE) - Diet Factor
Number of subjects: 301
Study: 27055107

Group type: EXPERIMENTAL
Intervention: Red yeast rice plus Coenzyme Q10
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24854611

Group type: EXPERIMENTAL
Intervention: Early refeeding (once bowel sounds returned)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Immediately full caloric diet
Number of subjects: 72

Group type: COMPARATOR
Intervention: Stepwise increasing diet
Number of subjects: 72

Group type: COMPARATOR
Intervention: Early refeeding
Number of subjects: 72
Study: 23064538

Group type: EXPERIMENTAL
Intervention: Herpes simplex virus (HSV‐1, 4.2%; HSV‐2, 98.2%) detected in genital ulcers
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Bacterial pathogens detected in genital ulcers
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: HIV, HSV‐2, and treponemal antibodies detected
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Urethral infections diagnosed
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: M. genitalium infections
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: T. vaginalis infections
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: C. trachomatis infections
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: N. gonorrhoeae infections
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Dysuria reported
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Urethral discharge on examination
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Urethral pathogens detected in men without clinical features
Number of subjects: 615
Study: 20004957

Group type: EXPERIMENTAL
Intervention: Nerve-sparing technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional radical hysterectomy
Number of subjects: 20
Study: 18575162

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of 0.1 mg morphine, 0.015 mg fentanyl and 15 mg hyperbaric bupivacaine (Group I, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Psoas compartment block with ropivacaine 0.475% 25 mL (Group II, n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of 0.1 mg morphine, 0.015 mg fentanyl and 15 mg hyperbaric bupivacaine (Group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Psoas compartment block with ropivacaine 0.475% 25 mL (Group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions (Group I and Group II)
Number of subjects: 40
Study: 16093971

Group type: EXPERIMENTAL
Intervention: Hexaminolevulinate (HAL) fluorescence cystoscopy
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard white light cystoscopy
Number of subjects: 146
Study: 12616845

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacoepidemiological studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: National registry for drug-induced QT prolongation
Number of subjects: 0
Study: 10561636

Group type: COMPARATOR
Intervention: 50‐g glucose beverage
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 28 jelly beans (50 g simple carbohydrate)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both sugar sources
Number of subjects: 160
Study: 8916999

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 mg, 12 h prior to surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vaginal misoprostol 800 mg, 2 to 4 hours prior to surgery
Number of subjects: 60
Study: 1863010

Group type: EXPERIMENTAL
Intervention: dipyridamole 75 mg three times daily and aspirin 330 mg once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: physical exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: physical exercise and dipyridamole 75 mg three times daily and aspirin 330 mg once daily
Number of subjects: 30
Study: 6843620

Group type: EXPERIMENTAL
Intervention: terbutaline with tube spacer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: terbutaline without tube spacer (conventional aerosol)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 31089727

Group type: EXPERIMENTAL
Intervention: eReferral (electronic health record-based referral)
Number of subjects: 14636
Study: 27733091

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (200 U)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 25522840

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 42
Study: 23866345

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 369
Study: 21118796

Group type: EXPERIMENTAL
Intervention: Diammine silver fluoride
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sterile water (Control)
Number of subjects: 126
Study: 19880705

Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 0
Study: 17095617

Group type: EXPERIMENTAL
Intervention: New agents for the treatment of acute leukemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surrogate measures for clinical benefit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prospective randomized clinical trials
Number of subjects: 0
Study: 15143375

Group type: EXPERIMENTAL
Intervention: Nicotine patch therapy, education and motivation
Number of subjects: 634

Group type: COMPARATOR
Intervention: Education and motivation
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Nicotine patch therapy
Number of subjects: 634
Study: 10969304

Group type: EXPERIMENTAL
Intervention: Physostigmine (28 microgram/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Scopolamine (8.6 microgram/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 17
Study: 8771421

Group type: EXPERIMENTAL
Intervention: On-the-spot escorts present throughout the procedure
Number of subjects: 206

Group type: COMPARATOR
Intervention: Waiting-room escorts
Number of subjects: 206
Study: 1299499

Group type: EXPERIMENTAL
Intervention: 40 mg.kg‐1 L‐ornithine.HCl
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg.kg‐1 L‐ornithine.HCl
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 170 mg.kg‐1 L‐ornithine.HCl
Number of subjects: 12
Study: 6744203

Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Chemotherapy (6 cycles of Adriamycin (45 mg/m2), vincristine (1.2 mg/m2), and cyclophosphamide (200 mg/m2 for 5 days) every 4 weeks)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined treatment (radiotherapy and chemotherapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Levamisole immunotherapy (150 mg a day, 2 days weekly)
Number of subjects: 120
Study: 31504891

Group type: EXPERIMENTAL
Intervention: Eggs from hens aged 32 weeks
Number of subjects: 6048

Group type: EXPERIMENTAL
Intervention: Egg storage for 7 days
Number of subjects: 6048

Group type: EXPERIMENTAL
Intervention: Egg storage for 10 days
Number of subjects: 6048

Group type: EXPERIMENTAL
Intervention: Egg storage for 13 days
Number of subjects: 6048

Group type: EXPERIMENTAL
Intervention: Egg storage for 17 days
Number of subjects: 6048

Group type: EXPERIMENTAL
Intervention: Hens aged 38, 46, and 51 weeks
Number of subjects: 6048
Study: 29886075

Group type: EXPERIMENTAL
Intervention: High-intensity agility program (15 sessions, 3 weeks)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: High-intensity agility program
Number of subjects: 72

Group type: COMPARATOR
Intervention: No physical intervention control
Number of subjects: 72
Study: 1564302

Group type: EXPERIMENTAL
Intervention: Acute i.v. administration of erythromycin (500 mg every 8 hours for 24 hours)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Chronic oral therapy with erythromycin (500 mg three times daily for 15 weeks)
Number of subjects: 1
Study: 22576305

Group type: EXPERIMENTAL
Intervention: Acacia senegal barrier
Number of subjects: 60

Group type: COMPARATOR
Intervention: Zinc sulfate ointment
Number of subjects: 60
Study: 20537151

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study: 18662628

Group type: EXPERIMENTAL
Intervention: Sevoflurane (expired end‐tidal concentration 1%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo oxygen/air mix
Number of subjects: 30
Study: 15966092

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study: 12595326

Group type: EXPERIMENTAL
Intervention: Radiographers reporting
Number of subjects: 400

Group type: COMPARATOR
Intervention: Consultant radiologists reporting
Number of subjects: 400
Study: 10910673

Group type: EXPERIMENTAL
Intervention: Smoking pregnant women
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-smoking pregnant women
Number of subjects: 0
Study: 8964395

Group type: EXPERIMENTAL
Intervention: Budesonide 10 mg daily
Number of subjects: 72

Group type: COMPARATOR
Intervention: Prednisolone 40 mg daily
Number of subjects: 72
Study: 1889023

Group type: EXPERIMENTAL
Intervention: levobunolol eyedrops
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo drops
Number of subjects: 10
Study: 3875389

Group type: EXPERIMENTAL
Intervention: Vincristine, Methotrexate, Folinic acid rescue, and Cisplatin (VMP)
Number of subjects: 28
Study: 30682445

Group type: EXPERIMENTAL
Intervention: Sipuleucel-T alone (Arm A)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Sipuleucel-T after sensitizing radiation therapy (Arm B)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 49
Study: 29566437

Group type: EXPERIMENTAL
Intervention: Bimagrumab 10 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26991468

Group type: EXPERIMENTAL
Intervention: Oral pentoxyfylline 400 mg thrice daily for 3 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo tablet thrice daily for 3 weeks
Number of subjects: 110
Study: 25267413

Group type: EXPERIMENTAL
Intervention: Upper alpha neurofeedback (25 min session)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 19
Study: 22569029

Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg kg(‐1) following remifentanil infusion at 0.5 μg kg(‐1) min(‐1)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (normal cognitive function, MMSE score 25 or higher)
Number of subjects: 92
Study: 20010613

Group type: EXPERIMENTAL
Intervention: Silver-alginate-containing dressing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 100
Study: 17915162

Group type: EXPERIMENTAL
Intervention: PI-NEV arm (ddI + d4T + nelfinavir)
Number of subjects: 137

Group type: COMPARATOR
Intervention: NEV-PI arm (ddI + d4T + nevirapine)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: PI-NEV arm
Number of subjects: 137

Group type: COMPARATOR
Intervention: NEV-PI arm
Number of subjects: 137
Study: 17876489

Group type: EXPERIMENTAL
Intervention: Setting the tape loosely leaving a scissor tip gap between the tape and the urethra
Number of subjects: 0

Group type: COMPARATOR
Intervention: Setting the tape actually touching the urethra and covering the tape by the adjacent pubocervicovaginal fascia with the aid of a suture
Number of subjects: 0
Study: 15359898

Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: No-pravastatin group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness ratio for coronary heart disease
Number of subjects: 120
Study: 11419382

Group type: EXPERIMENTAL
Intervention: Intervening target-absent lineup exposure
Number of subjects: 160
Study: 9407256

Group type: EXPERIMENTAL
Intervention: Amino acid supplement (2.9 g.day-1) containing leucine, isoleucine, valine, glutamine, and carnitine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lactose (3 g.day-1)
Number of subjects: 14
Study: 8171216

Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg two times daily for 3 months
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 3513752

Group type: EXPERIMENTAL
Intervention: Methamphetamine (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenmetrazine (25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phentermine (37.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pemoline (75 mg)
Number of subjects: 0
Study: 11491175

Group type: EXPERIMENTAL
Intervention: Prednisolone treatment (5 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo treatment (5 days)
Number of subjects: 13
Study: 30528698

Group type: EXPERIMENTAL
Intervention: 4Kscore
Number of subjects: 2872

Group type: EXPERIMENTAL
Intervention: Rotterdam Prostate Cancer Risk Calculator (RPCRC)
Number of subjects: 2872

Group type: EXPERIMENTAL
Intervention: Combination of RPCRC and 4Kscore
Number of subjects: 2872

Group type: COMPARATOR
Intervention: RPCRC
Number of subjects: 2872

Group type: EXPERIMENTAL
Intervention: RPCRC-4Kscore combination
Number of subjects: 2872
Study: 30107812

Group type: EXPERIMENTAL
Intervention: Unbalanced randomization
Number of subjects: 148
Study: 27481512

Group type: EXPERIMENTAL
Intervention: FEC (500/100/500)‐docetaxel (100)
Number of subjects: 2669

Group type: COMPARATOR
Intervention: FEC (500/100/500)‐docetaxel/gemcitabine (75/2000)
Number of subjects: 2669

Group type: EXPERIMENTAL
Intervention: G-CSF application (yes)
Number of subjects: 2669

Group type: COMPARATOR
Intervention: G-CSF application (no)
Number of subjects: 2669
Study: 24736628

Group type: EXPERIMENTAL
Intervention: Lobeglitazone 0.5 mg
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 22581064

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (HCl) for >6 months (median 37 months)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Calcium carbonate or no phosphate binder (Control group)
Number of subjects: 483
Study: 19846796

Group type: EXPERIMENTAL
Intervention: Closed-loop intraperitoneal insulin infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intraperitoneal open-loop insulin delivery (control)
Number of subjects: 8
Study: 18035206

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg/d
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg/d
Number of subjects: 24
Study: 15707858

Group type: EXPERIMENTAL
Intervention: Formoterol 36 microg TID via Aerolizer (total daily dose 108 microg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Salbutamol 600 microg TID via pMDI (total daily dose 1800 microg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Formoterol and Salbutamol
Number of subjects: 16
Study: 12385513

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 241
Study: 9951668

Group type: EXPERIMENTAL
Intervention: Honan intraocular pressure reducer (HIPR) applied for 10 minutes before surgery
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no HIPR)
Number of subjects: 51
Study: 7811178

Group type: EXPERIMENTAL
Intervention: Exercise at 40% of heart rate reserve (HRR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exercise at 60% of heart rate reserve (HRR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 40
Study: 1693496

Group type: EXPERIMENTAL
Intervention: Krypton red laser photocoagulation
Number of subjects: 496

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 496
Study: 272060

Group type: EXPERIMENTAL
Intervention: Cut toothbrush bristles (CP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Round ended toothbrush bristles (RP)
Number of subjects: 30
Study: 31397719

Group type: EXPERIMENTAL
Intervention: PHIV
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: PHEU
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: HUU
Number of subjects: 448
Study: 30128736

Group type: EXPERIMENTAL
Intervention: Internet-based self-management interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality criteria for self-management interventions
Number of subjects: 0
Study: 26890096

Group type: EXPERIMENTAL
Intervention: Active tDCS treatment (1 mA, 3 sessions per week for 6 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 18
Study: 24890443

Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Water Immersion (WI)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 270
Study: 21896676

Group type: EXPERIMENTAL
Intervention: Physiotherapy assessment/intervention
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group (no physiotherapy intervention)
Number of subjects: 186
Study: 20015525

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once a day added to pioglitazone 30 mg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice a day added to pioglitazone 15 mg
Number of subjects: 151
Study: 18061368

Group type: EXPERIMENTAL
Intervention: Telephone mode of assessment
Number of subjects: 457

Group type: COMPARATOR
Intervention: Mail mode of assessment
Number of subjects: 457

Group type: COMPARATOR
Intervention: Web-based mode of assessment
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Numeracy
Number of subjects: 457

Group type: COMPARATOR
Intervention: Telephone, Mail, Web-based modes
Number of subjects: 457
Study: 16117734

Group type: COMPARATOR
Intervention: HRT
Number of subjects: 80

Group type: COMPARATOR
Intervention: Exercise (Ex)
Number of subjects: 80

Group type: COMPARATOR
Intervention: HRT+exercise (ExHRT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Control (Co)
Number of subjects: 80
Study: 14598924

Group type: EXPERIMENTAL
Intervention: Lottery incentive offered to the intervention group for returning the questionnaire.
Number of subjects: 2543

Group type: COMPARATOR
Intervention: No incentive offered to the control group.
Number of subjects: 2543

Group type: EXPERIMENTAL
Intervention: Lottery incentive offered to the intervention group.
Number of subjects: 2543
Study: 11169057

Group type: EXPERIMENTAL
Intervention: 9 MU recombinant interferon beta-1a, three times per week (n=11)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 12 MU recombinant interferon beta-1a, three times per week (n=10)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Overall treatment (both doses)
Number of subjects: 21
Study: 8867263

Group type: EXPERIMENTAL
Intervention: Phentolamine 0.5 mg/kg over 20 min
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Phentolamine 1 mg/kg over 10 min
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (11 patients did not receive phentolamine)
Number of subjects: 117